AR020167A1 - Metodo para la prevencion del inicio del asma - Google Patents
Metodo para la prevencion del inicio del asmaInfo
- Publication number
- AR020167A1 AR020167A1 ARP990104039A ARP990104039A AR020167A1 AR 020167 A1 AR020167 A1 AR 020167A1 AR P990104039 A ARP990104039 A AR P990104039A AR P990104039 A ARP990104039 A AR P990104039A AR 020167 A1 AR020167 A1 AR 020167A1
- Authority
- AR
- Argentina
- Prior art keywords
- patient
- cetiricin
- asthma
- onset
- pharmaceutically acceptable
- Prior art date
Links
- 208000006673 asthma Diseases 0.000 title abstract 4
- 230000002265 prevention Effects 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 3
- 230000003287 optical effect Effects 0.000 abstract 2
- 206010070834 Sensitisation Diseases 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000007918 intramuscular administration Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000008313 sensitization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Uso de cetiricina, un isomero optico individual de la misma o una sal farmacéuticamente aceptable de la misma para la preparacion de un medicamentodestinado a la prevencion del inicio del asma en un paciente, siendo administrado dicho medicamento alpaciente de manera profiláctica antes del inicio delasma. El uso de cetiricina, también para la preparacion de un medicamento destinado a la prevencion de la sensibilizacion de un paciente al riesgo dedesarrollo de enfermedades asmáticas. La salpued e ser el diclorhidrato de cetiricina y el paciente es un bebé o un nino de 1 a 4 anos de edad. Laadministracion comprende una dosis diaria de 0,0005 mg hasta 2 mg de dicha cetiricina, dicho isomero optico individual de la misma o dichasalfarmacéutic amente aceptable de la misma, por kg de peso corporal del paciente y de 1 a 3 veces al día en forma intradérmica, transdérmica, de liberacion lenta,intramuscular, oral o intranasal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9692998P | 1998-08-18 | 1998-08-18 | |
| US9745598P | 1998-08-21 | 1998-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR020167A1 true AR020167A1 (es) | 2002-04-10 |
Family
ID=26792214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990104039A AR020167A1 (es) | 1998-08-18 | 1999-08-12 | Metodo para la prevencion del inicio del asma |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1109557B1 (es) |
| JP (1) | JP3878416B2 (es) |
| AR (1) | AR020167A1 (es) |
| AT (1) | ATE228366T1 (es) |
| AU (1) | AU749169B2 (es) |
| CA (1) | CA2340920C (es) |
| DE (1) | DE69904206T2 (es) |
| ES (1) | ES2188232T3 (es) |
| HN (1) | HN1999000140A (es) |
| MA (1) | MA26676A1 (es) |
| MY (1) | MY124089A (es) |
| PA (1) | PA8480401A1 (es) |
| SA (1) | SA99200492B1 (es) |
| TN (1) | TNSN99158A1 (es) |
| TW (1) | TW581675B (es) |
| WO (1) | WO2000010544A2 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002047689A2 (en) * | 2000-12-15 | 2002-06-20 | Ucb, S.A. | Use of cetirizine or efletirizine for preventing urticaria |
| WO2005077371A1 (en) * | 2004-02-12 | 2005-08-25 | Ucb Farchim Sa | Use of levocetirizine for the preparation of a drug |
| US8263581B2 (en) | 2009-07-03 | 2012-09-11 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
| US8513259B2 (en) | 2009-07-03 | 2013-08-20 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
-
1999
- 1999-07-23 TW TW088112517A patent/TW581675B/zh not_active IP Right Cessation
- 1999-08-12 AR ARP990104039A patent/AR020167A1/es not_active Application Discontinuation
- 1999-08-13 HN HN1999000140A patent/HN1999000140A/es unknown
- 1999-08-13 MY MYPI99003475A patent/MY124089A/en unknown
- 1999-08-13 MA MA25733A patent/MA26676A1/fr unknown
- 1999-08-14 EP EP99944395A patent/EP1109557B1/en not_active Expired - Lifetime
- 1999-08-14 ES ES99944395T patent/ES2188232T3/es not_active Expired - Lifetime
- 1999-08-14 JP JP2000565866A patent/JP3878416B2/ja not_active Expired - Fee Related
- 1999-08-14 AT AT99944395T patent/ATE228366T1/de not_active IP Right Cessation
- 1999-08-14 DE DE69904206T patent/DE69904206T2/de not_active Expired - Lifetime
- 1999-08-14 AU AU57346/99A patent/AU749169B2/en not_active Ceased
- 1999-08-14 WO PCT/EP1999/005969 patent/WO2000010544A2/en not_active Ceased
- 1999-08-14 CA CA002340920A patent/CA2340920C/en not_active Expired - Fee Related
- 1999-08-16 TN TNTNSN99158A patent/TNSN99158A1/fr unknown
- 1999-08-17 PA PA19998480401A patent/PA8480401A1/es unknown
- 1999-08-18 SA SA99200492A patent/SA99200492B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU5734699A (en) | 2000-03-14 |
| CA2340920A1 (en) | 2000-03-02 |
| EP1109557A2 (en) | 2001-06-27 |
| CA2340920C (en) | 2007-10-16 |
| MY124089A (en) | 2006-06-30 |
| HN1999000140A (es) | 2001-07-31 |
| MA26676A1 (fr) | 2004-12-20 |
| SA99200492B1 (ar) | 2006-06-04 |
| DE69904206D1 (de) | 2003-01-09 |
| TNSN99158A1 (ar) | 2005-11-10 |
| AU749169B2 (en) | 2002-06-20 |
| ES2188232T3 (es) | 2003-06-16 |
| DE69904206T2 (de) | 2003-07-17 |
| ATE228366T1 (de) | 2002-12-15 |
| JP3878416B2 (ja) | 2007-02-07 |
| TW581675B (en) | 2004-04-01 |
| WO2000010544A3 (en) | 2000-05-18 |
| WO2000010544A2 (en) | 2000-03-02 |
| EP1109557B1 (en) | 2002-11-27 |
| PA8480401A1 (es) | 2000-09-29 |
| JP2002523362A (ja) | 2002-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5023315B2 (ja) | 精神異常症の治療または予防処置のための、ミルタザピンと抗精神病剤の新規組み合わせ | |
| CU23468B7 (es) | Forma de dosificación de pramipexol en una dosis única diaria | |
| AU2017236177B2 (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| TW200817049A (en) | Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms | |
| ES2089027T3 (es) | Forma de dosificacion transmucosica. | |
| AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
| AR020803A1 (es) | Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento | |
| JPS59193821A (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| SK7532002A3 (en) | Pharmaceutical formulations containing zolmitriptan | |
| ES2236551T3 (es) | Combinacion de principios activos para el tratamiento medico de toxicomanias. | |
| KR970061244A (ko) | 치매 치료용 약학 조성물 | |
| ATE254463T1 (de) | Verwendung von valaciclovir zur herstellung eines arzneimittels zur behandlung von genitalherpes durch einmal tägliche verabreichung | |
| RU2010109359A (ru) | Азитромицин для лечения кожных заболеваний | |
| JPH0637395B2 (ja) | ジペプタイド誘導体を含有する、筋萎縮性側索硬化症を治療するための薬剤 | |
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| AR035946A1 (es) | Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos | |
| WO2003079976A3 (en) | A substance with sedative effect | |
| AR020167A1 (es) | Metodo para la prevencion del inicio del asma | |
| BR0316131A (pt) | Acetil-l-carnitina para a prevenção e/ou tratamento de neuropatias periféricas induzidas por agentes anti-câncer | |
| ES2312657T3 (es) | Utilizacion de desoxipeganina en el tratamiento de la depresion clinica. | |
| CN104758445A (zh) | 一种烟叶提取物及其在依赖治疗中的应用 | |
| ES2275619T3 (es) | Quetiapina para el tratamiento de discinesia en pacientes no psicoticos. | |
| JPH10506097A (ja) | Ｊｅｔ ｌａｇを緩和するための方法と医薬 | |
| ES2303585T3 (es) | Combinacion de glivec(sti571) con un inhibidor de quinasa dependiente de ciclina, especialmente flavopiridol en el tratamiento de cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |